AC Immune planning NASDAQ listing

Neurology company AC Immune S.A. (Lausanne, Switzerland) filed to raise up to $50 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies and Leerink Partners.

AC Immune's lead program is crenezumab ( RG7412), a humanized mAb against beta amyloid to treat prodromal to mild Alzheimer's disease. Its partner, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), began a Phase III study of the candidate in 1Q16. ...